scholarly journals Second non-breast primary cancer following adjuvant therapy for early breast cancer: A report from the International Breast Cancer Study Group

2009 ◽  
Vol 45 (4) ◽  
pp. 561-571 ◽  
Author(s):  
Lorenzo Gianni ◽  
Shari Gelber ◽  
Alberto Ravaioli ◽  
Karen N. Price ◽  
Ilaria Panzini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Early Breast Cancer ◽  
Study Group ◽  
Primary Cancer ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Breast Cancer Study

Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI

2007 ◽  
Vol 43 (11) ◽  
pp. 1646-1653 ◽  
Author(s):  
Ann Partridge ◽  
Shari Gelber ◽  
Richard D. Gelber ◽  
Monica Castiglione-Gertsch ◽  
Aron Goldhirsch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Long Term Results ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Breast Cancer Study

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1992 ◽  
Vol 10 (7) ◽  
pp. 1049-1056 ◽  
Author(s):  
B A Gusterson ◽  
R D Gelber ◽  
A Goldhirsch ◽  
K N Price ◽  
J Säve-Söderborgh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Study Group ◽  
Primary Tumors ◽  
Node Negative ◽  
Cancer Study ◽  
Node Positive ◽  
Cancer Study Group ◽  
Breast Cancer Study ◽  
Prognostic Importance

PURPOSE To evaluate the prognostic importance of immunocytochemically determined c-erbB-2 overexpression in the primary tumors of patients with breast cancer. PATIENTS AND METHODS Primary tumors from 1,506 breast cancer patients (760 node-negative and 746 node-positive) who were treated in the International (Ludwig) Breast Cancer Study Group Trial V were studied. Node-negative patients were allocated randomly to either a single cycle of perioperative chemotherapy (PeCT) or no adjuvant treatment, and node-positive patients received either a prolonged chemotherapy (with tamoxifen for postmenopausal patients) or a single perioperative cycle. RESULTS Tumors from 16% of the node-negative patients and 19% of the node-positive patients were found to be c-erbB-2-positive. In both groups c-erbB-2 positivity correlated with negative progesterone receptors (PR), negative estrogen receptors (ER), and high tumor grade. Lobular carcinomas were all negative, and, thus support the view that such tumors represent a defined subtype of breast carcinoma. The expression of c-erbB-2 was prognostically significant for node-positive but not for node-negative patients. However, in both subgroups, the prognostic significance was greater for patients who had received more adjuvant therapy. For node-positive patients, the effect of prolonged-duration therapy on disease-free survival (DFS) was greater for patients without c-erbB-2 overexpression (hazards ratio [HR], = 0.57; 95% confidence interval [CI], 0.46 to 0.72) than for those with c-erbB-2 overexpression (HR, 0.77; 95% CI, 0.51 to 1.16). Similarly, for node-negative patients, the effect of PeCT on DFS was greater for those without c-erbB-2 overexpression (HR, 0.82; 95% CI, 0.61 to 1.09) than for those with c-erbB-2 overexpression (HR, 1.22; 95% CI, 0.66 to 2.25). CONCLUSION We conclude that tumors with overexpression of the c-erbB-2 oncogene are less responsive to cyclophosphamide, methotrexate, and fluorouracil (CMF)-containing adjuvant therapy regimens than those with a normal amount of gene product.

Sign in / Sign up

Export Citation Format

Share Document